NCT06141031View on ClinicalTrials.gov

Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Pancreatic Cancer
Interventions
DRUG

TTI-101

TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.

Trial Locations (1)

80045

RECRUITING

University of Colorado, Aurora

All Listed Sponsors
collaborator

Tvardi Therapeutics, Incorporated

INDUSTRY

lead

University of Colorado, Denver

OTHER